Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damag...
Saved in:
Published in | Journal of neuroinflammation Vol. 22; no. 1; pp. 45 - 20 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
21.02.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. |
---|---|
AbstractList | Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNF[alpha], IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. Keywords: Intracerebral hemorrhage, Brain injury, Inflammation, Oxidative stress, Lipid peroxidation, Ferroptosis, Hematoma clearance, Cluster of differentiation, Antioxidant, Neuroprotection, Cinnamaldehyde, Deferoxamine Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. Abstract Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNF[alpha], IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. |
ArticleNumber | 45 |
Audience | Academic |
Author | Yang, Guoqiang Mazhar, Maryam Xu, Houping Liu, Yulin Zhang, Yuwei Liu, Mengnan |
Author_xml | – sequence: 1 givenname: Yulin surname: Liu fullname: Liu, Yulin – sequence: 2 givenname: Guoqiang surname: Yang fullname: Yang, Guoqiang – sequence: 3 givenname: Mengnan surname: Liu fullname: Liu, Mengnan – sequence: 4 givenname: Yuwei surname: Zhang fullname: Zhang, Yuwei – sequence: 5 givenname: Houping surname: Xu fullname: Xu, Houping – sequence: 6 givenname: Maryam surname: Mazhar fullname: Mazhar, Maryam |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39985048$$D View this record in MEDLINE/PubMed |
BookMark | eNptkstu1DAUhiNURC_wAixQJDYsSPEttrNCVcWlUiU2sLZO4uMZV4k92BnoPAmvizNTqo6EvIhjf_7k4_OfVychBqyq15RcUqrlh0xZp0RDWNsQzhVvds-qM6oEaxjpxMmT-Wl1nvMdIZy1kr2oTnnX6ZYIfVb9ufYhwASjxfXOYg3B1n7O9RCn3geYfQz1bz-va4sOU7yHyYdCTTj6mGDG2gc3wjTtyfd1YVLczDH7vFetsezECWq830DIiw3cjKkcmxMMmLBPMC5YTGkNq8VXT37Al9VzB2PGVw_fi-rH50_fr782t9--3Fxf3TaD0GpuLHLOW6ta0Vmqeq0tE1xQqbgkqNwgiCRE09bRQbRApeCadw6VJoKplip-Ud0cvDbCndkkP0HamQje7BdiWhlIsx9GNEVge02YA2UF6_sOLBkkOMFd15ff4vp4cG22_YR2wKXG8Uh6vBP82qziL1O6KaQo7bmo3j0YUvy5xTybyecBxxECxm02nMquJVIyXtC3B3QF5W6lC3F50AU3V5rpYutoW6jL_1BlWCyvXOLkfFk_OvDmaQ2Pl_-XmAKwAzCkmHNC94hQshQizSGWpsTS7GNpdvwvlhLXpw |
Cites_doi | 10.1016/S2214-109X(13)70089-5 10.1016/j.cell.2012.03.042 10.1371/journal.pone.0193615 10.1002/acn3.485 10.1111/jnc.12974 10.1038/sigtrans.2017.23 10.3390/ijms23147977 10.1002/ctm2.965 10.1126/science.7100929 10.1016/S1474-4422(24)00369-7 10.1161/STROKEAHA.109.569830 10.1007/s007020070051 10.3171/jns.2004.100.4.0672 10.1007/s00109-013-1007-3 10.1161/STROKEAHA.115.011956 10.1016/j.mam.2020.100851 10.1182/blood-2005-03-1185 10.1523/JNEUROSCI.3776-09.2009 10.1016/S1474-4422(19)30069-9 10.1021/acsbiomaterials.2c00236 10.1016/j.lfs.2023.121814 10.1155/2020/10343252020 10.1111/cns.13399 10.1161/STROKEAHA.121.037298 10.1080/01480545.2017.1417995 10.1038/nchembio.2239 10.1016/j.brainres.2019.146514 10.14800/ttnd.474 10.1055/s-0036-1582132 10.1111/bph.13270 10.3389/fphys.2014.00415 10.1007/s11011-019-00480-7 10.1016/j.jtha.2024.06.028 10.1093/brain/123.10.2046 10.1080/01616412.1997.11740874 10.1161/CIRCRESAHA.121.319949 10.1016/j.wneu.2021.06.117 10.7554/eLife.35316 10.1016/j.plipres.2022.101207 10.1016/j.bbadis.2021.166204 10.1038/s41572-023-00424-7 10.1038/s41580-020-00324-8 10.1186/1742-2094-10-27 10.1155/2013/523652 10.1016/j.phymed.2024.155791 10.5853/jos.2016.00864 10.3390/ijms222111313 10.1016/S1474-4422(09)70340-0 10.1038/s41420-021-00553-6 10.1089/ars.2012.4834 10.1016/j.pharmthera.2023.108373 10.1038/s41420-024-02049-5 10.1080/21688370.2016.1251384 10.1016/S1474-4422(12)70104-7 10.1111/j.1749-6632.2010.05735.x 10.1172/jci.insight.90777 10.1097/01.WCB.0000073905.87928.6D 10.3390/molecules24081583 10.1016/j.expneurol.2019.05.003 10.12688/f1000research.20510.1 10.1213/ANE.0b013e3181d568c8 10.1038/jcbfm.2010.209 10.1016/j.bbr.2014.01.052 10.1007/s00701-010-0750-2 10.1161/STROKEAHA.110.596718 10.1016/j.cmet.2015.09.006 10.1111/acel.13235 10.1038/s41418-020-00685-9 10.1007/s40828-022-00163-4 10.3390/biom11111615 10.1161/STROKEAHA.117.016850 10.1080/10408390902773052 10.1161/STROKEAHA.123.045194 10.1016/j.nbd.2017.03.016 10.1016/j.bbamcr.2019.118535 10.1111/jcmm.13441 10.1016/j.ejphar.2021.174622 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s12974-025-03373-y |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1742-2094 |
EndPage | 20 |
ExternalDocumentID | oai_doaj_org_article_45adb802fa7d42bb9ad0c6af43f9bbb9 PMC11846400 A828400915 39985048 10_1186_s12974_025_03373_y |
Genre | Journal Article |
GeographicLocations | China United States Newfoundland and Labrador |
GeographicLocations_xml | – name: China – name: Newfoundland and Labrador – name: United States |
GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
ID | FETCH-LOGICAL-c487t-de3335d7549d17b88d2434167360e7fc40600815f1c45a1643839fe7804275173 |
IEDL.DBID | DOA |
ISSN | 1742-2094 |
IngestDate | Wed Aug 27 01:14:45 EDT 2025 Thu Aug 21 18:27:14 EDT 2025 Fri Jul 11 10:44:32 EDT 2025 Tue Jun 17 21:59:38 EDT 2025 Tue Jun 10 21:08:25 EDT 2025 Sat May 10 01:40:29 EDT 2025 Tue Jul 01 05:36:01 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Neuroprotection Oxidative stress Cinnamaldehyde Cluster of differentiation Hematoma clearance Lipid peroxidation Ferroptosis Inflammation Antioxidant Brain injury Intracerebral hemorrhage Deferoxamine |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c487t-de3335d7549d17b88d2434167360e7fc40600815f1c45a1643839fe7804275173 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/45adb802fa7d42bb9ad0c6af43f9bbb9 |
PMID | 39985048 |
PQID | 3169506623 |
PQPubID | 23479 |
PageCount | 20 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_45adb802fa7d42bb9ad0c6af43f9bbb9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11846400 proquest_miscellaneous_3169506623 gale_infotracmisc_A828400915 gale_infotracacademiconefile_A828400915 pubmed_primary_39985048 crossref_primary_10_1186_s12974_025_03373_y |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-02-21 |
PublicationDateYYYYMMDD | 2025-02-21 |
PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-21 day: 21 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of neuroinflammation |
PublicationTitleAlternate | J Neuroinflammation |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | U Lendeckel (3373_CR11) 2022; 8 C Sturgeon (3373_CR73) 2016; 4 L Puy (3373_CR25) 2023; 9 M Mazhar (3373_CR37) 2021; 7 SJ Dixon (3373_CR8) 2012; 149 P Garland (3373_CR65) 2016; 47 Q Li (3373_CR49) 2017; 2 A di Masi (3373_CR63) 2020; 73 T Liu (3373_CR31) 2017; 2 S Javaid (3373_CR44) 2021 PR Krafft (3373_CR22) 2014; 264 H Fang (3373_CR32) 2013; 10 X Zhao (3373_CR10) 2009; 40 H Wu (3373_CR14) 2011; 31 A Etzerodt (3373_CR67) 2013; 18 VL Feigin (3373_CR1) 2024; 23 KR Wagner (3373_CR7) 2003; 23 M Roy-O’Reilly (3373_CR68) 2017; 4 M Błaż (3373_CR72) 2024 S Doll (3373_CR54) 2017; 13 V Hvidberg (3373_CR61) 2005; 106 R Liu (3373_CR71) 2017; 48 K Sahebi (3373_CR79) 2024; 10 Y Liu (3373_CR23) 2020; 26 3373_CR58 M Selim (3373_CR28) 2019; 18 JH Thomsen (3373_CR64) 2013; 2013 X Zhao (3373_CR60) 2009; 29 B Gürer (3373_CR20) 2019; 34 PW Pires (3373_CR27) 2018; 7 SJ An (3373_CR2) 2017; 19 MH Askenase (3373_CR30) 2016; 36 S Hu (3373_CR69) 2019; 318 X Jiang (3373_CR45) 2021; 22 X Diao (3373_CR40) 2020; 1727 M Selim (3373_CR12) 2009; 40 M Hajinejad (3373_CR17) 2020 CM Stuart (3373_CR75) 2022; 12 WM Clark (3373_CR21) 1997; 19 DM Feeney (3373_CR24) 1982; 217 X Zhao (3373_CR59) 2015; 133 J Aronowski (3373_CR9) 2011; 42 M Okauchi (3373_CR13) 2010; 41 OA Harari (3373_CR33) 2010; 1207 S Yan (3373_CR55) 2024; 132 RF Keep (3373_CR6) 2012; 11 YW Kim (3373_CR35) 2013; 91 G Wang (3373_CR66) 2018; 22 H Drakesmith (3373_CR51) 2015; 22 H Cheng (3373_CR56) 2021; 1867 J Magid-Bernstein (3373_CR26) 2022; 130 RV Krishnamurthi (3373_CR3) 2013; 1 L Foster (3373_CR15) 2022; 53 M Dorri (3373_CR47) 2018; 41 J Gruenwald (3373_CR16) 2010; 50 I Costa (3373_CR57) 2023; 244 L Zeng (3373_CR29) 2018; 13 3373_CR38 DJ Schaer (3373_CR62) 2014; 5 3373_CR34 WD Bao (3373_CR52) 2021; 28 3373_CR76 J Zhao (3373_CR18) 2015; 172 CJ van Asch (3373_CR4) 2010; 9 P Kuru Bektaşoğlu (3373_CR19) 2021; 153 D Galaris (3373_CR36) 2019; 1866 G Wang (3373_CR77) 2011; 153 J Fang (3373_CR53) 2021; 913 3373_CR39 CF Chang (3373_CR78) 2017; 103 AM Astudillo (3373_CR46) 2023; 89 T Nakamura (3373_CR48) 2004; 100 3373_CR74 MR Garnett (3373_CR43) 2000; 123 X Zhao (3373_CR70) 2024; 55 J Klein (3373_CR42) 2000; 107 J Elliott (3373_CR5) 2010; 110 D Neves (3373_CR41) 2023; 328 WD Bao (3373_CR50) 2020; 19 |
References_xml | – volume: 40 start-page: S90 issue: 3suppl1 year: 2009 ident: 3373_CR12 publication-title: Stroke – volume: 1 start-page: e259 issue: 5 year: 2013 ident: 3373_CR3 publication-title: Lancet Global Health doi: 10.1016/S2214-109X(13)70089-5 – volume: 149 start-page: 1060 issue: 5 year: 2012 ident: 3373_CR8 publication-title: Cell doi: 10.1016/j.cell.2012.03.042 – volume: 13 start-page: e0193615 issue: 3 year: 2018 ident: 3373_CR29 publication-title: PLoS ONE doi: 10.1371/journal.pone.0193615 – volume: 4 start-page: 793 issue: 11 year: 2017 ident: 3373_CR68 publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.485 – volume: 133 start-page: 144 issue: 1 year: 2015 ident: 3373_CR59 publication-title: J Neurochem doi: 10.1111/jnc.12974 – volume: 2 start-page: 17023 year: 2017 ident: 3373_CR31 publication-title: Signal Transduct Target Therapy doi: 10.1038/sigtrans.2017.23 – ident: 3373_CR34 doi: 10.3390/ijms23147977 – volume: 12 start-page: e965 issue: 7 year: 2022 ident: 3373_CR75 publication-title: Clin Translational Med doi: 10.1002/ctm2.965 – volume: 217 start-page: 855 issue: 4562 year: 1982 ident: 3373_CR24 publication-title: Sci (New York NY) doi: 10.1126/science.7100929 – volume: 23 start-page: 973 issue: 10 year: 2024 ident: 3373_CR1 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(24)00369-7 – volume: 41 start-page: 375 issue: 2 year: 2010 ident: 3373_CR13 publication-title: Stroke doi: 10.1161/STROKEAHA.109.569830 – volume: 107 start-page: 1027 issue: 8–9 year: 2000 ident: 3373_CR42 publication-title: J Neural Transmission (Vienna Austria: 1996) doi: 10.1007/s007020070051 – volume: 100 start-page: 672 issue: 4 year: 2004 ident: 3373_CR48 publication-title: J Neurosurg doi: 10.3171/jns.2004.100.4.0672 – volume: 91 start-page: 323 issue: 3 year: 2013 ident: 3373_CR35 publication-title: J Mol Med doi: 10.1007/s00109-013-1007-3 – volume: 47 start-page: 872 issue: 3 year: 2016 ident: 3373_CR65 publication-title: Stroke doi: 10.1161/STROKEAHA.115.011956 – volume: 73 start-page: 100851 year: 2020 ident: 3373_CR63 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2020.100851 – volume: 106 start-page: 2572 issue: 7 year: 2005 ident: 3373_CR61 publication-title: Blood doi: 10.1182/blood-2005-03-1185 – volume: 29 start-page: 15819 issue: 50 year: 2009 ident: 3373_CR60 publication-title: J Neuroscience: Official J Soc Neurosci doi: 10.1523/JNEUROSCI.3776-09.2009 – volume: 18 start-page: 428 issue: 5 year: 2019 ident: 3373_CR28 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30069-9 – ident: 3373_CR58 doi: 10.1021/acsbiomaterials.2c00236 – volume: 328 start-page: 121814 year: 2023 ident: 3373_CR41 publication-title: Life Sci doi: 10.1016/j.lfs.2023.121814 – year: 2020 ident: 3373_CR17 publication-title: Biomed Res Int doi: 10.1155/2020/10343252020 – volume: 26 start-page: 1031 issue: 10 year: 2020 ident: 3373_CR23 publication-title: CNS Neurosci Ther doi: 10.1111/cns.13399 – volume: 53 start-page: 2204 issue: 7 year: 2022 ident: 3373_CR15 publication-title: Stroke doi: 10.1161/STROKEAHA.121.037298 – volume: 41 start-page: 338 issue: 3 year: 2018 ident: 3373_CR47 publication-title: Drug Chem Toxicol doi: 10.1080/01480545.2017.1417995 – volume: 13 start-page: 91 issue: 1 year: 2017 ident: 3373_CR54 publication-title: Nat Chem Biol doi: 10.1038/nchembio.2239 – volume: 1727 start-page: 146514 year: 2020 ident: 3373_CR40 publication-title: Brain Res doi: 10.1016/j.brainres.2019.146514 – ident: 3373_CR76 doi: 10.14800/ttnd.474 – volume: 36 start-page: 288 issue: 3 year: 2016 ident: 3373_CR30 publication-title: Semin Neurol doi: 10.1055/s-0036-1582132 – volume: 172 start-page: 5009 issue: 20 year: 2015 ident: 3373_CR18 publication-title: Br J Pharmacol doi: 10.1111/bph.13270 – volume: 5 start-page: 415 year: 2014 ident: 3373_CR62 publication-title: Front Physiol doi: 10.3389/fphys.2014.00415 – volume: 34 start-page: 1737 issue: 6 year: 2019 ident: 3373_CR20 publication-title: Metab Brain Dis doi: 10.1007/s11011-019-00480-7 – volume: 40 start-page: S92 issue: 3suppl1 year: 2009 ident: 3373_CR10 publication-title: Stroke – year: 2024 ident: 3373_CR72 publication-title: J Thromb Haemost doi: 10.1016/j.jtha.2024.06.028 – volume: 123 start-page: 2046 issue: Pt 10 year: 2000 ident: 3373_CR43 publication-title: Brain doi: 10.1093/brain/123.10.2046 – volume: 19 start-page: 641 issue: 6 year: 1997 ident: 3373_CR21 publication-title: Neurol Res doi: 10.1080/01616412.1997.11740874 – volume: 130 start-page: 1204 issue: 8 year: 2022 ident: 3373_CR26 publication-title: Circul Res doi: 10.1161/CIRCRESAHA.121.319949 – volume: 153 start-page: e392 year: 2021 ident: 3373_CR19 publication-title: World Neurosurg doi: 10.1016/j.wneu.2021.06.117 – volume: 7 start-page: e35316 year: 2018 ident: 3373_CR27 publication-title: eLife doi: 10.7554/eLife.35316 – volume: 89 start-page: 101207 year: 2023 ident: 3373_CR46 publication-title: Prog Lipid Res doi: 10.1016/j.plipres.2022.101207 – volume: 1867 start-page: 166204 issue: 12 year: 2021 ident: 3373_CR56 publication-title: Biochim et Biophys acta Mol Basis Disease doi: 10.1016/j.bbadis.2021.166204 – volume: 9 start-page: 14 issue: 1 year: 2023 ident: 3373_CR25 publication-title: Nat Reviews Disease Primers doi: 10.1038/s41572-023-00424-7 – volume: 22 start-page: 266 issue: 4 year: 2021 ident: 3373_CR45 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/s41580-020-00324-8 – volume: 10 start-page: 27 year: 2013 ident: 3373_CR32 publication-title: J Neuroinflamm doi: 10.1186/1742-2094-10-27 – volume: 2013 start-page: 523652 year: 2013 ident: 3373_CR64 publication-title: Oxidative Med Cell Longev doi: 10.1155/2013/523652 – volume: 132 start-page: 155791 year: 2024 ident: 3373_CR55 publication-title: Phytomedicine: Int J Phytotherapy Phytopharmacology doi: 10.1016/j.phymed.2024.155791 – volume: 19 start-page: 3 issue: 1 year: 2017 ident: 3373_CR2 publication-title: J Stroke doi: 10.5853/jos.2016.00864 – year: 2021 ident: 3373_CR44 publication-title: Int J Mol Sci doi: 10.3390/ijms222111313 – volume: 9 start-page: 167 issue: 2 year: 2010 ident: 3373_CR4 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70340-0 – volume: 7 start-page: 149 issue: 1 year: 2021 ident: 3373_CR37 publication-title: Cell Death Discovery doi: 10.1038/s41420-021-00553-6 – volume: 18 start-page: 2352 issue: 17 year: 2013 ident: 3373_CR67 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2012.4834 – volume: 244 start-page: 108373 year: 2023 ident: 3373_CR57 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2023.108373 – volume: 10 start-page: 321 issue: 1 year: 2024 ident: 3373_CR79 publication-title: Cell Death Discovery doi: 10.1038/s41420-024-02049-5 – volume: 4 start-page: e1251384 issue: 4 year: 2016 ident: 3373_CR73 publication-title: Tissue Barriers doi: 10.1080/21688370.2016.1251384 – volume: 11 start-page: 720 issue: 8 year: 2012 ident: 3373_CR6 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70104-7 – volume: 1207 start-page: 32 year: 2010 ident: 3373_CR33 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2010.05735.x – volume: 2 start-page: e90777 issue: 7 year: 2017 ident: 3373_CR49 publication-title: JCI Insight doi: 10.1172/jci.insight.90777 – volume: 23 start-page: 629 issue: 6 year: 2003 ident: 3373_CR7 publication-title: J Cereb Blood flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism doi: 10.1097/01.WCB.0000073905.87928.6D – ident: 3373_CR38 doi: 10.3390/molecules24081583 – volume: 318 start-page: 244 year: 2019 ident: 3373_CR69 publication-title: Exp Neurol doi: 10.1016/j.expneurol.2019.05.003 – ident: 3373_CR74 doi: 10.12688/f1000research.20510.1 – volume: 110 start-page: 1419 issue: 5 year: 2010 ident: 3373_CR5 publication-title: Anesth Analg doi: 10.1213/ANE.0b013e3181d568c8 – volume: 31 start-page: 1243 issue: 5 year: 2011 ident: 3373_CR14 publication-title: J Cereb Blood flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism doi: 10.1038/jcbfm.2010.209 – volume: 264 start-page: 151 year: 2014 ident: 3373_CR22 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2014.01.052 – volume: 153 start-page: 319 issue: 2 year: 2011 ident: 3373_CR77 publication-title: Acta Neurochir doi: 10.1007/s00701-010-0750-2 – volume: 42 start-page: 1781 issue: 6 year: 2011 ident: 3373_CR9 publication-title: Stroke doi: 10.1161/STROKEAHA.110.596718 – volume: 22 start-page: 777 issue: 5 year: 2015 ident: 3373_CR51 publication-title: Cell Metabol doi: 10.1016/j.cmet.2015.09.006 – volume: 19 start-page: e13235 issue: 11 year: 2020 ident: 3373_CR50 publication-title: Aging Cell doi: 10.1111/acel.13235 – volume: 28 start-page: 1548 issue: 5 year: 2021 ident: 3373_CR52 publication-title: Cell Death Differ doi: 10.1038/s41418-020-00685-9 – volume: 8 start-page: 12 issue: 2 year: 2022 ident: 3373_CR11 publication-title: Chemtexts doi: 10.1007/s40828-022-00163-4 – ident: 3373_CR39 doi: 10.3390/biom11111615 – volume: 48 start-page: 1369 issue: 5 year: 2017 ident: 3373_CR71 publication-title: Stroke doi: 10.1161/STROKEAHA.117.016850 – volume: 50 start-page: 822 issue: 9 year: 2010 ident: 3373_CR16 publication-title: Crit Rev Food Sci Nutr doi: 10.1080/10408390902773052 – volume: 55 start-page: 166 issue: 1 year: 2024 ident: 3373_CR70 publication-title: Stroke doi: 10.1161/STROKEAHA.123.045194 – volume: 103 start-page: 54 year: 2017 ident: 3373_CR78 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2017.03.016 – volume: 1866 start-page: 118535 issue: 12 year: 2019 ident: 3373_CR36 publication-title: Biochim et Biophys acta Mol cell Res doi: 10.1016/j.bbamcr.2019.118535 – volume: 22 start-page: 768 issue: 2 year: 2018 ident: 3373_CR66 publication-title: J Cell Mol Med doi: 10.1111/jcmm.13441 – volume: 913 start-page: 174622 year: 2021 ident: 3373_CR53 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2021.174622 |
SSID | ssj0032562 |
Score | 2.4476595 |
Snippet | Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available.... Abstract Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 45 |
SubjectTerms | Acrolein - administration & dosage Acrolein - analogs & derivatives Acrolein - therapeutic use Aldehydes Analysis Animals Antioxidants Blood lipids Brain Brain damage Brain injury Care and treatment Cell death Cerebral Hemorrhage - complications Cerebral Hemorrhage - drug therapy Cerebral Hemorrhage - metabolism Cerebral Hemorrhage - pathology Deferoxamine Deferoxamine - administration & dosage Deferoxamine - therapeutic use Diagnosis Dosage and administration Drug Therapy, Combination Enzyme-linked immunosorbent assay Ferroptosis Ferroptosis - drug effects Ferroptosis - physiology Glutamate Haptoglobin Health aspects Hematoma Hematoma - drug therapy Hematoma - etiology Hematoma - pathology Hemoglobin Inflammation Inflammation - drug therapy Inflammation - etiology Injuries Intracerebral hemorrhage Lipid peroxidation Male Membrane lipids Mice Mice, Inbred C57BL Oxidative stress Oxidative Stress - drug effects Siderophores - administration & dosage |
Title | Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39985048 https://www.proquest.com/docview/3169506623 https://pubmed.ncbi.nlm.nih.gov/PMC11846400 https://doaj.org/article/45adb802fa7d42bb9ad0c6af43f9bbb9 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtCqWX0nfcposKhR5aEVuSLfmYhIRQSCilgb0JyZLZhV072A5kf0n_bmfk3bCmh156tCXbsubTPGzNN4R8FkqXtqwdS52tmRReM10Iy-oy-NRW0lYWE4WvrovLG_l9ns_3Sn3hnrCRHnicuGOZW-90ymurvOTOldanVWFrKerSwSFqX7B5u2Bq1MECDDnfpcjo4rgHq6Ykw9KtqRBKsM3EDEW2_r918p5Rmm6Y3LNAFy_I863rSE_GIb8kj0Lzijy92v4cf01-ny2bxq7tyofFxgdqG0-XQ08BUxD-RglQ_OxKPZLLtvd2DZdRuw4rTNMfAgWwAT7GXMZvFPp07e3Q9ss-3iqyu7ZrS8M9aBD8yEZjgXG4DEZbhQ5_Qa-wW9t1C1BT0ECx2P0bcnNx_uvskm3rLrAKwpeB-SCEyL2C0NFnymntuQRjhzvA0qDqCnwA9CTyOqtAOhBvQZRb1gGpjLjKMyXekoOmbcIhoRneIOMhOGelCs6KSjtuC3AyeShCkZCvOzGY25Few8SwRBdmFJoBoZkoNLNJyClK6qEnUmPHEwAYswWM-RdgEvIF5WxwAeP02G0eAgwYqbDMCcSgoNjKLE_I0aQnLLxq0vxphxSDTbhbrQntXW9EVpQ5UuuLhLwbkfMwZnAIdQ5qMyF6gqnJS01bmuUi8n7DrMgCnv3-f0zDB_KMx_XAGc-OyMHQ3YWP4F8NbkYeq7makSen59c_fs7iwvoDRDErbg |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cinnamaldehyde+and+its+combination+with+deferoxamine+ameliorate+inflammation%2C+ferroptosis+and+hematoma+expansion+after+intracerebral+hemorrhage+in+mice&rft.jtitle=Journal+of+neuroinflammation&rft.au=Liu%2C+Yulin&rft.au=Yang%2C+Guoqiang&rft.au=Liu%2C+Mengnan&rft.au=Zhang%2C+Yuwei&rft.date=2025-02-21&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12974-025-03373-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12974_025_03373_y |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |